WallStSmart

Merck & Company Inc (MRK)vsOlink Holding AB ADR (OLK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 38854% more annual revenue ($66.57B vs $170.89M). MRK leads profitability with a 4.8% profit margin vs -19.7%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

OLK

Avoid

19

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 4.0Quality: 8.0
Piotroski: 1/9Altman Z: 3.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
OLKSignificantly Overvalued (-49.5%)

Margin of Safety

-49.5%

Fair Value

$17.45

Current Price

$26.08

$8.63 premium

UndervaluedFair: $17.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

OLK2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.2010/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

OLK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-7.0%2/10

ROE of -7.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : OLK

The strongest argument for OLK centers on Debt/Equity, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : OLK

The primary concerns for OLK are Revenue Growth, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while OLK is a turnaround play — different risk/reward profiles.

OLK carries more volatility with a beta of 0.52 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Olink Holding AB ADR

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology and other institutions focused on life science research. The company is headquartered in Uppsala, Sweden.

Want to dig deeper into these stocks?